Phase I/II Study of TG4050 in Patients with Stage III/IV HPV-Negative Squamous-Cell Carcinoma of the Head and Neck Post-Surgery and Adjuvant Therapy

The primary objective of this study is to evaluate the safety and tolerability of **TG4050**, an individualized gene therapy, in patients with advanced cancer of the head and neck. This is clinically relevant as it aims to determine the potential of TG4050 to be a viable treatment option for patients with newly diagnosed, stage III or IV, HPV-negative, squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx (SCCHN) who have completed and achieved a documented complete response to gross total resection of the primary tumor and standard adjuvant therapy.

The clinical trial involves a total of **20 participants** diagnosed with newly diagnosed, stage III or IV HPV negative, **squamous-cell carcinoma** of the oral cavity, oropharynx, hypopharynx, or larynx. These participants have completed and documented a complete response to gross total resection of the primary tumor and standard adjuvant therapy. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically includes adults and older adults. The trial population was selected to include individuals who are part of a vulnerable population. Participants' general health status is characterized by their ability to undergo surgery and respond to adjuvant therapy. Lifestyle considerations such as diet, physical activity, and habits are not specified in the available data. The selection criteria for this trial ensure that the participants have a specific medical condition and treatment history, although detailed inclusion or exclusion criteria are not provided by the sponsor.

The clinical trial is designed to evaluate the efficacy and safety of an individualized gene therapy, TG4050, in patients with advanced **squamous-cell carcinoma of the head and neck** (SCCHN). This trial is structured as a **randomized, double-blind, controlled** study, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial commenced on December 16, 2019, and is projected to conclude by December 30, 2027, encompassing a comprehensive duration to assess long-term outcomes.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening to confirm eligibility based on specific criteria, such as having a newly diagnosed, stage III or IV HPV-negative SCCHN that is amenable to surgery. Following the inclusion visit, participants will attend regular follow-up visits to monitor their response to the therapy and any potential side effects. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will culminate in an end-of-study visit, where final assessments will be conducted to evaluate the overall impact of the treatment.

The expected length of participant involvement in the trial is contingent upon the individual's response to the treatment and adherence to the study protocol. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study requirements, or if the investigator deems it in the participant's best interest to withdraw. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding of TG4050's potential as a therapeutic option for SCCHN.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. Consequently, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. As such, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. Therefore, no further details can be offered in this context.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to conclude by December 30, 2027, with recruitment having commenced on December 16, 2019. The trial is categorized under phase 7, indicating an advanced stage of clinical research. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, the trial will likely employ standard methodologies for measuring and analyzing efficacy outcomes. These may include validated scales, laboratory tests, or patient-reported outcomes, assessed at predetermined timepoints throughout the trial duration. The absence of explicit endpoints suggests a focus on comprehensive data collection to evaluate the therapeutic impact of the intervention under investigation.